Barclays has initiated coverage on Organon & Co (OGN), assigning an Underweight rating to the pharmaceutical company. This marks the firm's first assessment of Organon's investment potential based on its research and analysis of the business and industry dynamics.
Organon & Co, headquartered in Jersey City, New Jersey, specializes in developing innovative health solutions, particularly in women's health, biosimilars, and established medicines. The company boasts a portfolio of approximately 70 products, including contraception and fertility brands like Nexplanon and NuvaRing. With a market capitalization of $1.9 billion, Organon reported a price of $7.33 per share at the time of the rating.
The announcement highlights the mixed sentiment surrounding the company, reflected in the current analyst consensus, which includes 0 Strong Buy, 1 Buy, 6 Hold, 7 Sell, and 1 Strong Sell recommendations. As of December 1, 2025, the consensus rating is Sell.
Investment decisions should consider various factors, including company fundamentals, competitive positioning, and industry trends. Analyst ratings, while informative, represent professional opinions based on assumptions that may not always materialize as expected. As such, they should be one of many inputs in evaluating investment choices.
Upcoming earnings reports are anticipated, with estimates of $1.04 EPS and $1.6 billion in revenue for the quarter ending August 3, 2026. This follows a strong Q3 2025 performance where the company reported an EPS of $1.01, exceeding expectations by 6.8%.